publication date: Jan. 2, 2015

NCI CTEP-Approved Trials for the Month of December

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

9608: A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors. Mayo Clinic Cancer Center LAO; Costello, Brian A. (507) 266-5365

 

PBTC-044: A Pediatric Brain Tumor Consortium Phase I Study of Buparlisib (BKM120) in Recurrent or Refractory Primary CNS Tumors. Pediatric Brain Tumor Consortium; Cho, Yoon-Jae. (650) 725-0955

 

Phase II

AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma. Children’s Oncology Group; DuBois, Steven G. (415) 476-4764

 

Phase III

AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL). Children’s Oncology Group; Brown, Patrick A. (410) 614-4915

 

AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents. Children’s Oncology Group; Castellino, Sharon M. (336) 716-4085

 

Other Phases

A151303: Clinical Impact of Genomic Variants in Follicular Lymphoma Treated on CALGB/Alliance Clinical Trials. Alliance for Clinical Trials in Oncology; Fehniger, Todd A. (314) 747-1385

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.